Advances in drug delivery-based therapeutic strategies for renal fibrosis treatment

Abstract

The ultimate consequence of all chronic kidney illnesses is renal fibrosis, which is posing a growing threat to global health. Currently, traditional treatments for renal fibrosis are difficult to meet the clinical needs due to shortcomings such as poor efficacy or high toxic side effects. Therefore, therapeutic strategies that target to the kidney are needed to break this dilemma. Drug delivery can be attained via improving drug stability and addressing controlled release and targeted delivery of drugs in the delivery category. By combining drug delivery technology with nanosystems, controlled drug release and biodistribution can be achieved, enhancing therapeutic efficacy and dropping toxic crosswise effects. This review discusses the nanomaterial drug delivery strategies in recent years. Firstly, it describes the mechanisms of renal fibrosis and anti-renal fibrosis drug delivery, secondly, it highlights different nanomaterial drug delivery strategies for the treatment of renal injury and fibrosis, and finally, it discusses the shortcomings of such strategies.